From the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital, Houston, TX.
Conflicts of Interest and Source of Funding: P.D.L. and M.B. have patent applications in the field of adoptive cell therapy of cancer, and M.B. is an equity holder or Scientific Advisory Board member of companies (Allovir, Tessa, Marker Therapeutics, Allogene, Kuur, Walking Fish, Turnstone Biologics, Posedia, Tscan, Bluebird Bio, Adaptimmune Therapeutics, Adintus, Onkimure, Triumvira Immunologics, Bellicum Pharmaceuticals, Memgen LLC, Brooklyn, Immunotherapeutics, Coya, and AstraZeneca Pharmaceuticals) who are developing cellular therapies for cancer. M.B. receives royalties from Takeda and Bellicum. Support was provided by NIH SPORE in Lymphoma 5P50CA126752, Leukemia Lymphoma Society SCOR 7019-19, CPRIT Early Career Clinical Investigator Award (RP200584).
Reprints: Premal D. Lulla, MD, Center for Cell and Gene Therapy, 1102 Bates Ave (Feigin Center), Suite 1770.6, Houston, TX 77030. E-mail: [email protected].
